Search

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor and Pharmaceutical Use Therefor

The USPTO granted patent US12605359B2 to THE KITASATO INSTITUTE on April 21, 2026, covering a low-molecular weight compound that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) functions. The patent protects the compound represented by formula (I), its pharmaceutically acceptable salts and solvates, and medicaments containing the PCSK9 inhibitor for prevention or treatment of PCSK9-related diseases and disorders. The patent contains 5 claims.